Merck and Endocyte withdraw regulatory apps

|By:, SA News Editor

Merck (MRK +0.9%) and development partner Endocyte (ECYT -0.5%) withdraw their conditional marketing authorization applications from the European Medicines Agency for vintafolide and companion imaging components, imaging agent etarfolatide and IV folic acid, for the treatment of adults with folate receptor-positive , platinim-resistant ovarian cancer, in combination with pegylated liposomal doxorubicin. The companies' action is based on further analyses of interim data from the Proceed clinical trial. Earlier this month, The Data Safety Monitoring Board recommended stopping the trial due to the lack of efficacy.